Orion’s collaborator, MSD, has expanded the development program for opevestostat (MK-5684) to now include women’s cancers. A new Phase 2 clinical trial evaluating the safety and efficacy of ...
Orion Corporation (“Orion”) and MSD (tradename of Merck & Co., Inc. Rahway NJ USA) today announced a global development and commercialisation agreement for Orion’s investigational candidate ODM-208 ...
SINGAPORE, October 21, 2011 - MSD, known as Merck in the United States and Canada, and the Singapore Economic Development Board today jointly announced the signing of a new agreement under which MSD ...
Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3 Evaxion will host a conference call and webcast to discuss the agreement on ...
Orion to receive an upfront payment of USD 290 million Agreement strengthens and complements MSD’s oncology pipeline Orion Corporation (“Orion”) and MSD (tradename of Merck & Co., Inc. Rahway NJ USA) ...
Orion and MSD announce global collaboration for the development and commercialisation of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback